Contract facts
NONENo full NAICS 325412 intel page yet. Browse NAICS intelligence
:COVID-19: MODIFICATION TO EXERCISE OPTIONS 1001 AND 2001 FOR ORAL ANTIVIRAL MK-4482 (MOLNUPIRAVIR) TREATMENT DOSES. is a federal NONE award for Department of Defense (DOD) held by Merck Sharp & Dohme Corp. Estimated value $2.2B ($997M obligated). Current period of performance ends Sep 30, 2023. Last award drew 1 bidder. Place of performance: KENILWORTH, NJ. Related solicitation W911QY20SC001.
:COVID-19: MODIFICATION TO EXERCISE OPTIONS 1001 AND 2001 FOR ORAL ANTIVIRAL MK-4482 (MOLNUPIRAVIR) TREATMENT DOSES.
Recompete timing
PublicCurrent PoP ended Sep 30, 2023 (1098 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on W911QY21C0031? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordMerck Sharp & Dohme Corp — $7.7B obligated across 101 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W911QY21C0031?
W911QY21C0031 (:covid-19: modification to exercise options 1001) is a W6qk Acc-Apg Natick award with an estimated value of $2.2B, currently held by Merck Sharp & Dohme Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is W911QY-21-C-0031?
W911QY-21-C-0031 is the dashed form of PIID W911QY21C0031 (:covid-19: modification to exercise options 1001), held by Merck Sharp & Dohme Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded W911QY21C0031?
W6qk Acc-Apg Natick awarded W911QY21C0031 to Merck Sharp & Dohme Corp.
Who is the incumbent on W911QY21C0031?
Merck Sharp & Dohme Corp is the incumbent with $7.7B across 101 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2023.
When does Merck Sharp & Dohme Corp’s W911QY21C0031 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on W911QY21C0031? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.